173 related articles for article (PubMed ID: 12193930)
1. The differential diagnostic potential of a panel of tumor markers (CA 125, CA 15-3, and CA 72-4 antigens) in patients with a pelvic mass.
Schutter EM; Davelaar EM; van Kamp GJ; Verstraeten RA; Kenemans P; Verheijen RH
Am J Obstet Gynecol; 2002 Aug; 187(2):385-92. PubMed ID: 12193930
[TBL] [Abstract][Full Text] [Related]
2. Estimation of probability of malignancy using a logistic model combining physical examination, ultrasound, serum CA 125, and serum CA 72-4 in postmenopausal women with a pelvic mass: an international multicenter study.
Schutter EM; Sohn C; Kristen P; Möbus V; Crombach G; Kaufmann M; Caffier H; Kreienberg R; Verstraeten AA; Kenemans P
Gynecol Oncol; 1998 Apr; 69(1):56-63. PubMed ID: 9570999
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic value of pelvic examination, ultrasound, and serum CA 125 in postmenopausal women with a pelvic mass. An international multicenter study.
Schutter EM; Kenemans P; Sohn C; Kristen P; Crombach G; Westermann R; Môbus V; Kaufmann M; Caffier H; Schmidt-Rhode P
Cancer; 1994 Aug; 74(4):1398-406. PubMed ID: 8055463
[TBL] [Abstract][Full Text] [Related]
4. Combination of multiple serum markers using an artificial neural network to improve specificity in discriminating malignant from benign pelvic masses.
Zhang Z; Barnhill SD; Zhang H; Xu F; Yu Y; Jacobs I; Woolas RP; Berchuck A; Madyastha KR; Bast RC
Gynecol Oncol; 1999 Apr; 73(1):56-61. PubMed ID: 10094881
[TBL] [Abstract][Full Text] [Related]
5. Studies on angiogenesis in the benign and malignant ovarian neoplasms with the use of color and pulsed Doppler sonography and serum CA-125, CA-19.9, CA-72.4 and vascular endothelial growth factor measurements.
Czekierdowski A
Ann Univ Mariae Curie Sklodowska Med; 2002; 57(1):113-31. PubMed ID: 12898913
[TBL] [Abstract][Full Text] [Related]
6. Clinical performance of LOCI™-based tumor marker assays for tumor markers CA 15-3, CA 125, CEA, CA 19-9 and AFP in gynecological cancers.
Dolscheid-Pommerich RC; Keyver-Paik M; Hecking T; Kuhn W; Hartmann G; Stoffel-Wagner B; Holdenrieder S
Tumour Biol; 2017 Oct; 39(10):1010428317730246. PubMed ID: 29034816
[TBL] [Abstract][Full Text] [Related]
7. [The values of serum human epididymis secretory protein 4 and CA(125) assay in the diagnosis of ovarian malignancy].
Dong L; Chang XH; Ye X; Zhu LR; Zhao Y; Tian L; Cheng HY; Li XP; Zhang H; Liao QP; Fu TY; Cheng YX; Cui H
Zhonghua Fu Chan Ke Za Zhi; 2008 Dec; 43(12):931-6. PubMed ID: 19134334
[TBL] [Abstract][Full Text] [Related]
8. Clinical value of human epididymis protein 4 and the Risk of Ovarian Malignancy Algorithm in differentiating borderline pelvic tumors from epithelial ovarian cancer in early stages.
Kotowicz B; Fuksiewicz M; Sobiczewski P; Spiewankiewicz B; Jonska-Gmyrek J; Skrzypczak M; Kowalska M
Eur J Obstet Gynecol Reprod Biol; 2015 Nov; 194():141-6. PubMed ID: 26398337
[TBL] [Abstract][Full Text] [Related]
9. Role of CA125/CEA ratio and ultrasound parameters in identifying metastases to the ovaries in patients with multilocular and multilocular-solid ovarian masses.
Moro F; Pasciuto T; Djokovic D; Di Legge A; Granato V; Moruzzi MC; Mancari R; Zannoni GF; Fischerova D; Franchi D; Scambia G; Testa AC
Ultrasound Obstet Gynecol; 2019 Jan; 53(1):116-123. PubMed ID: 29978587
[TBL] [Abstract][Full Text] [Related]
10. Role of biomarkers CA-125, CA-15.3 and CA-19.9 in the distinction between endometriomas and ovarian neoplasms.
Magalhães JS; Jammal MP; Crispim PCA; Murta EFC; Nomelini RS
Biomarkers; 2021 May; 26(3):268-274. PubMed ID: 33554683
[TBL] [Abstract][Full Text] [Related]
11. Risk of malignancy index used as a diagnostic tool in a tertiary centre for patients with a pelvic mass.
Håkansson F; Høgdall EV; Nedergaard L; Lundvall L; Engelholm SA; Pedersen AT; Hartwell D; Høgdall C;
Acta Obstet Gynecol Scand; 2012 Apr; 91(4):496-502. PubMed ID: 22229703
[TBL] [Abstract][Full Text] [Related]
12. Development of a multimarker assay for differential diagnosis of benign and malignant pelvic masses.
Chen X; Zhou H; Chen R; He J; Wang Y; Huang L; Sun L; Duan C; Luo X; Yan H
Clin Chim Acta; 2015 Feb; 440():57-63. PubMed ID: 25447698
[TBL] [Abstract][Full Text] [Related]
13. CA 19-9 in evaluation of adnexal mass: retrospective cohort analysis and review of the literature.
Sagi-Dain L; Lavie O; Auslander R; Sagi S
Int J Biol Markers; 2015 Jul; 30(3):e333-40. PubMed ID: 25704505
[TBL] [Abstract][Full Text] [Related]
14. Urinary gonadotropin peptide (UGP) and serum CA 125 in gynaecologic practice, a clinical prospective study.
Schutter EM; Mijatovic V; Kok A; Van Kamp GJ; Verstraeten R; Verheijen RH
Anticancer Res; 1999; 19(6C):5551-7. PubMed ID: 10697615
[TBL] [Abstract][Full Text] [Related]
15. Ascites as a predictor of ovarian malignancy.
Shen-Gunther J; Mannel RS
Gynecol Oncol; 2002 Oct; 87(1):77-83. PubMed ID: 12468346
[TBL] [Abstract][Full Text] [Related]
16. Comparison of Doppler with two-dimensional sonography and CA 125 for prediction of malignancy of pelvic masses.
Schneider VL; Schneider A; Reed KL; Hatch KD
Obstet Gynecol; 1993 Jun; 81(6):983-8. PubMed ID: 8497367
[TBL] [Abstract][Full Text] [Related]
17. Differential diagnosis of ovarian cancer with tumour markers CA 125, CA 15-3 and TAG 72.3.
Jacobs IJ; Rivera H; Oram DH; Bast RC
Br J Obstet Gynaecol; 1993 Dec; 100(12):1120-4. PubMed ID: 8297846
[TBL] [Abstract][Full Text] [Related]
18. Significance of some tumor markers in differential diagnosis of ovarian tumor.
Zakrzewska I; Borawska R; Poznański J; Maćkowiak B
Rocz Akad Med Bialymst; 1999; 44():235-43. PubMed ID: 10697438
[TBL] [Abstract][Full Text] [Related]
19. Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer.
Zhang Z; Yu Y; Xu F; Berchuck A; van Haaften-Day C; Havrilesky LJ; de Bruijn HW; van der Zee AG; Woolas RP; Jacobs IJ; Skates S; Chan DW; Bast RC
Gynecol Oncol; 2007 Dec; 107(3):526-31. PubMed ID: 17920110
[TBL] [Abstract][Full Text] [Related]
20. A prospective study to evaluate the risk malignancy index and its diagnostic implication in patients with suspected ovarian mass.
Dora SK; Dandapat AB; Pande B; Hota JP
J Ovarian Res; 2017 Aug; 10(1):55. PubMed ID: 28806987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]